Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery-Reference-Cited by-同舟云学术

Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery

Published:2007-05-22 Issue:7 Volume:31 Page:1458-1468
ISSN:0364-2313
Container-title:World Journal of Surgery
language:en
Short-container-title:World J Surg

Author:

Galizia Gennaro,Lieto Eva,Orditura Michele,Castellano Paolo,Mura Anna La,Imperatore Vincenzo,Pinto Margherita,Zamboli Anna,De Vita Ferdinando,Ferraraccio Francesca

Publisher

Springer Science and Business Media LLC

Subject

Surgery

Link

http://link.springer.com/content/pdf/10.1007/s00268-007-9016-4.pdf

Reference33 articles.

1. Jemal A, Siegel R, Ward E, et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

2. Hartgrink HH, van de Velde CJ (2005) Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer: J Surg Oncol 90:153–165

3. Novotny AR, Schuhmaker C, Bush R, et al. (2006) Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 243:74–81

4. Ajani JA, Mansfield PF, Crane CH, et al. (2005) Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23:1237–1244

5. Allal AS, Zwahlen D, Brundler MA, et al. (2005) Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 63:1286–1289

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases;Scientific Reports;2024-06-03

2. Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2;Hematology/Oncology Clinics of North America;2024-06

3. Integrated PBPK-EO Modeling of Osimertinib: Predicting Pharmacokinetics, Intracranial EGFR Engagement, and Optimal Dosing Strategies in Clinical Settings;2024-01-12

4. BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis;Advanced Science;2023-10-20

5. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor;Pharmacological Reviews;2023-06-20